Cargando…
Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants
RAS guanosine triphosphatases (GTPases) are mutated in nearly 20% of human tumors, making them an attractive therapeutic target. Following our discovery that nucleotide-free RAS (apo RAS) regulates cell signaling, we selectively target this state as an approach to inhibit RAS function. Here, we desc...
Autores principales: | Khan, Imran, Koide, Akiko, Zuberi, Mariyam, Ketavarapu, Gayatri, Denbaum, Eric, Teng, Kai Wen, Rhett, J. Matthew, Spencer-Smith, Russell, Hobbs, G. Aaron, Camp, Ernest Ramsay, Koide, Shohei, O’Bryan, John P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936000/ https://www.ncbi.nlm.nih.gov/pubmed/35139380 http://dx.doi.org/10.1016/j.celrep.2022.110322 |
Ejemplares similares
-
Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket
por: Wallon, Lauren, et al.
Publicado: (2022) -
Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors
por: Akkapeddi, Padma, et al.
Publicado: (2023) -
Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation
por: Sha, Fern, et al.
Publicado: (2023) -
Selective and noncovalent targeting of RAS mutants for inhibition and degradation
por: Teng, Kai Wen, et al.
Publicado: (2021) -
Mutations in the α4-α5 allosteric lobe of RAS do not significantly impair RAS signaling or self-association
por: Whaby, Michael, et al.
Publicado: (2022)